Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

National Heart, Lung, and Blood Institute

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Determination of Red Cell Survival in Sickle Cell Disease and Other Hemoglobinopathies Using Biotin Labeling

Early Phase 1

Recruiting

Conditions: Sickle Cell Disease
Thalassemia
Hemoglobinopathy

Interventions: Biological: Biotin-labeled red blood cells

First Posted Date: 2024-03-15

Last Posted Date: 2025-04-23

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 100

Registration Number: NCT06313398

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Multi-Scale Analysis of Phenotypes in Heart Failure (MAP-HEART)

Conditions: Heart Failure

First Posted Date: 2024-02-28

Last Posted Date: 2025-07-03

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 2000

Registration Number: NCT06280820

Locations: 🇺🇸
INOVA Fairfax Hospital, Falls Church, Virginia, United States

NHLBI SESAME (SEptal Scoring Along Midline Endocardium) Early Feasibility Study

Not Applicable

Recruiting

Conditions: Hypertrophic Cardiomyopathy
Mitral Valve Disease
Left Ventricular Septal Hypertrophy
Aortic Valve Stenosis

Interventions: Device: Septal Scoring Along Midline Endocardium

First Posted Date: 2024-02-21

Last Posted Date: 2025-06-06

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 30

Registration Number: NCT06269640

Locations: 🇺🇸
St Francis Hospital and Heart Center, Roslyn, New York, United States
🇺🇸
Emory University Hospital, Atlanta, Georgia, United States

Non-myeloablative Haploidentical HCT Study for Patients With Sickle Cell Disease, Including Compromised Organ Function

Phase 1

Active, not recruiting

Conditions: Sickle Cell Disease

Interventions: Drug: Non-myeloablative haploidentical peripheral blood stem cell transplantation with briquilimab and abatacept

First Posted Date: 2023-11-24

Last Posted Date: 2025-04-10

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 6

Registration Number: NCT06145282

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Early Detection of Infectious and Noninfectious Lung Diseases Following Allogeneic Hematopoietic Stem Cell Transplantation

Recruiting

Conditions: Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

First Posted Date: 2023-10-23

Last Posted Date: 2025-04-11

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 40

Registration Number: NCT06093867

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Double-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus Erythematosus

Phase 1

Recruiting

Conditions: Systemic Lupus Erythematosus (Sle)

Interventions: Dietary Supplement: Nicotinamide Riboside

First Posted Date: 2023-09-13

Last Posted Date: 2025-06-08

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 78

Registration Number: NCT06032923

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

JAK/STAT Inhibition in CNS Kohlmeier-Degos Disease

Phase 1

Completed

Conditions: Kohlmeier Degos Disease With Neurologic Involvement

Interventions: Drug: Ruxolitinib

First Posted Date: 2023-08-21

Last Posted Date: 2025-04-20

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 1

Registration Number: NCT05998395

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

JAK1/2 Inhibitor Ruxolitinib for Relapsed/Refractory Immune Bone Marrow Failure

Phase 1

Recruiting

Conditions: Hypoplastic MDS
Single Lineage Cytopenias, T-LGL
Severe Aplastic Anemia

Interventions: Drug: Ruxolitinib

First Posted Date: 2023-08-21

Last Posted Date: 2025-06-04

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 145

Registration Number: NCT05998408

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Study of Intravenous ZMA001 in Healthy Subjects

Phase 1

Suspended

Conditions: Pulmonary Arterial Hypertension PAH

Interventions: Other: Placebo
Drug: ZMA001 (BC-NKA-20008)

First Posted Date: 2023-08-01

Last Posted Date: 2025-05-18

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 20

Registration Number: NCT05967299

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease

Phase 1

Recruiting

Conditions: Sickle Cell Disease
Hb-SS Disease
Hemoglobin S
Disease Sickle Cell Anemia
Sickle Cell Disorders
Hemoglobin Beta Thalassemia Disease

Interventions: Drug: Fostamatinib

First Posted Date: 2023-06-15

Last Posted Date: 2025-04-20

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 25

Registration Number: NCT05904093

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy